Ogawa J, Inoue H, Koide S, Kawada S, Shohtsu A
1st Dept. of Surgery, Tokai University, Kanagawa.
Gan To Kagaku Ryoho. 1988 Aug;15(8):2265-71.
Interactions between fluorinated Pyrimidine derivatives and anticoagulants were studied experimentally and clinically, using transplanted tumor tissues of Donryu rats and tissues from lung cancer patients. In rats, which were given 5-FU, uracil, tegafur and UFT respectively, the higher tumor concentrations of 5-FU and uracil were observed when given warfarin and ticlopidine beforehand, on the other hand, the concentrations of tegafur were almost the same between rats with and without anticoagulants. In patients with lung cancer, who were given UFT and anticoagulants, the higher concentrations of 5-FU and uracil in plasma, tumor and lymph nodes were observed than those who were given UFT alone. The 5-FU concentrations in normal lung tissues were about a half of those in tumor. These results suggest a existence of the synergistic effects between fluorinated pyrimidine derivatives and anticoagulants in plasma and tissue concentrations of 5-FU.
使用Donryu大鼠的移植肿瘤组织和肺癌患者的组织,对氟嘧啶衍生物与抗凝剂之间的相互作用进行了实验和临床研究。在分别给予5-氟尿嘧啶(5-FU)、尿嘧啶、替加氟和优福定(UFT)的大鼠中,预先给予华法林和噻氯匹定后,观察到5-FU和尿嘧啶的肿瘤浓度较高,另一方面,使用抗凝剂和未使用抗凝剂的大鼠中替加氟的浓度几乎相同。在给予优福定和抗凝剂的肺癌患者中,观察到血浆、肿瘤和淋巴结中5-FU和尿嘧啶的浓度高于仅给予优福定的患者。正常肺组织中的5-FU浓度约为肿瘤中的一半。这些结果表明,在5-FU的血浆和组织浓度方面,氟嘧啶衍生物与抗凝剂之间存在协同作用。